PharmaPendium®
Fact Sheet

PharmaPendium Efficacy Module

Gain insights from precedent efficacy data across multiple parameters that help to optimize drug candidate selection and to mitigate the risk of suboptimal clinical trial study designs.
Help Improve Phase I and Phase II clinical trial success rates

During the drug development process, pharmaceutical companies face many challenges, some of which result in late-stage failures. With Phase II efficacy-related failure rates as high as 57%, many companies are seeking ways to improve their outcomes and reduce the climbing $2.6 billion costs to get one drug to market. As clinical trials become increasingly more complex and costly, it is even more critical to mitigate the risk of failed clinical trials or arms due to suboptimal study design or poor efficacy.

PHARMAPENDIUM EFFICACY MODULE

The PharmaPendium Efficacy Module helps researchers rapidly find deeply enriched, comparative efficacy data extracted from FDA and EMA drug approval documents—data that is critical to successful early clinical programs and often extremely difficult to find. And with the integrated views of preclinical and clinical efficacy data, researchers can also answer questions that have a significant impact on Phase I/II study designs, saving valuable time and potentially getting to market faster.

MAKE BETTER, MORE INFORMED DRUG DEVELOPMENT DECISIONS

Gain insights from precedent efficacy data across multiple parameters that help to optimize drug candidate selection and to mitigate the risk of suboptimal clinical trial study designs.

The comparative data provided in the Efficacy Module can help you make better clinical program decisions. In this figure, the inner circle represents the various parameters that could potentially lead to late-stage failures. The outside circle identifies how the PharmaPendium Efficacy Module can provide insights to each of these so researchers can make better more informed decisions.
TAXONOMIES AND RELEVANT FILTERS HELP FIND COMPARATIVE EFFICACY DATA RAPIDLY

As a unique source of human correlate data that bridges researchers’ needs for early efficacy data, the PharmaPendium Efficacy Module helps improve critical clinical development decisions. Rapid retrieval of disparate information is accomplished with relevant filters and taxonomies created to address the unique needs of efficacy-related searches including an indications and endpoint taxonomy.

Figure 1 Partial listing of the attributes in the new indication and endpoint taxonomies.

GAIN COMPREHENSIVE INSIGHTS ACROSS EFFICACY DATA AND REGULATORY CONTEXT IN MINUTES

Elsevier’s team of subject matter experts manually extracts efficacy-related data from FDA and EMA drug approval documents. The data is linked directly to the page and document from where it was extracted, so further insights can be gained from reviewer comments to help provide additional scientific direction and clarity for agency reviews.

KEY BENEFITS

- Normalized taxonomies and relevant filters enable rapid retrieval of data on critical efficacy-related parameters.
- Human correlate data can help to optimize translational models to better anticipate clinical adverse events.
- Mitigate potential clinical risks with comparative efficacy data from similar drug classes and target classes.
- Assess comparative off-target effects of similar drugs to better inform drug candidate selection.
- Find insights on any regulatory concerns that might mitigate the risk of repeating an arm of a clinical trial.
LEARN MORE

To request information or a product demonstration, please visit www.elsevier.com/online-tools/pharmapendium or contact your nearest Elsevier office.

ASIA AND AUSTRALIA
Tel: + 65 6349 0222
Email: sginfo@elsevier.com

JAPAN
Tel: + 81 3 5561 5034
Email: jpinfo@elsevier.com

KOREA AND TAIWAN
Tel: +82 2 6714 3000
Email: krinfo.corp@elsevier.com

EUROPE, MIDDLE EAST AND AFRICA
Tel: +31 20 485 3767
Email: nlinfo@elsevier.com

NORTH AMERICA, CENTRAL AMERICA AND CANADA
Tel: +1 888 615 4500
Email: usinfo@elsevier.com

SOUTH AMERICA
Tel: +55 21 3970 9300
Email: brinfo@elsevier.com